cytarabine 100mg/ml injection solution for injection 100mg/ml (20ml)
pfizer hellas s.a. 243 messoghion ave., neo psychiko 15451, athens, greece - cytarabine - solution for injection - cytarabine 100 mg/ml - antineoplastic agents
cytarabine 20 mg/ml solution for injection/infusion (2ml vial)
accord healthcare ireland ltd euro house, euro business park, little island cork, t45 k857, ireland - cytarabine - solution for injection/infusion - cytarabine 20 mg/ml - antineoplastic agents
cytarabine 20 mg/ml solution for injection/infusion (5ml vial)
accord healthcare ireland ltd euro house, euro business park, little island cork, t45 k857, ireland - cytarabine - solution for injection/infusion - cytarabine 20 mg/ml - antineoplastic agents
nevirapine 200mg tablets
wockhardt uk limited - nevirapine anhydrous - tablet - 200 milligram(s) - non-nucleoside reverse transcriptase inhibitors; nevirapine
nevirapine aurobindo 200mg tablets
aurobindo pharma (malta) limited vault 14, level 2, valletta waterfront, floriana frn 1913, malta - nevirapine - tablet - nevirapine 200 mg - antivirals for systemic use
nevirapine xr apotex nevirapine 400 mg modified release tablet blister pack
apotex pty ltd - nevirapine -
nevirapine 200 mg tablets
sandoz pharmaceuticals d.d. verovškova ulica 57, si-1000 ljubljana, slovenia - nevirapine - tablet - nevirapine 200 mg - antivirals for systemic use
nelarabine injection
zydus pharmaceuticals usa inc. - nelarabine (unii: 60158cv180) (nelarabine - unii:60158cv180) - nelarabine injection is indicated for the treatment of t-cell acute lymphoblastic leukemia (t-all) and t-cell lymphoblastic lymphoma (t-lbl) in adult and pediatric patients age 1 year and older whose disease has not responded to or has relapsed following treatment with at least two chemotherapy regimens. none. risk summary based on its mechanism of action and findings in animal studies, nelarabine can cause fetal harm when administered to a pregnant woman [see clinical pharmacology (12.1)] . limited available data with nelarabine use in pregnant women are insufficient to determine a drug-associated risk for major birth defects, miscarriage or adverse maternal or fetal outcomes. there are risks to the pregnant woman associated with untreated leukemia or lymphoma (see clinical considerations). in animal reproduction studies, intravenous administration of nelarabine to pregnant rabbits during the period of organogenesis resulted in teratogenicity at maternal doses below the recommended human adult dose of 1,500
nelarabine injection
zydus pharmaceuticals usa inc. - nelarabine (unii: 60158cv180) (nelarabine - unii:60158cv180) - nelarabine injection is indicated for the treatment of t-cell acute lymphoblastic leukemia (t-all) and t-cell lymphoblastic lymphoma (t-lbl) in adult and pediatric patients age 1 year and older whose disease has not responded to or has relapsed following treatment with at least two chemotherapy regimens. none. risk summary based on its mechanism of action and findings in animal studies, nelarabine can cause fetal harm when administered to a pregnant woman [see clinical pharmacology (12.1)] . limited available data with nelarabine use in pregnant women are insufficient to determine a drug-associated risk for major birth defects, miscarriage or adverse maternal or fetal outcomes. there are risks to the pregnant woman associated with untreated leukemia or lymphoma (see clinical considerations). in animal reproduction studies, intravenous administration of nelarabine to pregnant rabbits during the period of organogenesis resulted in teratogenicity at maternal doses below the recommended human adult dose of 1,500
nelarabine injection
dr. reddy's laboratories, inc. - nelarabine (unii: 60158cv180) (nelarabine - unii:60158cv180) - nelarabine injection is indicated for the treatment of t-cell acute lymphoblastic leukemia (t-all) and t-cell lymphoblastic lymphoma (t-lbl) in adult and pediatric patients age 1 year and older whose disease has not responded to or has relapsed following treatment with at least two chemotherapy regimens. none. risk summary based on its mechanism of action and findings in animal studies, nelarabine can cause fetal harm when administered to a pregnant woman [ see clinical pharmacology ( 12.1) ]. limited available data with nelarabine use in pregnant women are insufficient to determine a drug-associated risk for major birth defects, miscarriage or adverse maternal or fetal outcomes. there are risks to the pregnant woman associated with untreated leukemia or lymphoma (see clinical considerations ). in animal reproduction studies, intravenous administration of nelarabine to pregnant rabbits during the period of organogenesis resulted in teratogenicity at maternal doses below the recommended human adult dose of